Lawmakers Should Reject Big Pharma’s Debunked Rhetoric on Innovation, Hold
Brand Name Manufacturers Accountable to Foster Greater Generic and Biosimilar
Competition





 



CSRxP ENCOURAGES HELP COMMITTEE TO BUILD MOMENTUM BEHIND BIPARTISAN SOLUTIONS
TO LOWER PRESCRIPTION DRUG PRICES BY FOSTERING GREATER COMPETITION

Lawmakers Should Reject Big Pharma’s Debunked Rhetoric on Innovation, Hold
Brand Name Manufacturers Accountable to Foster Greater Generic and Biosimilar
Competition



Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released
the following statement ahead of a Thursday hearing titled “Making Medicines
More Affordable: How Competition Can Lower Drug Prices” in the U.S. Senate
Committee on Health, Education, Labor and Pensions (HELP).



“Big Pharma’s egregious pricing practices and anti-competitive tactics are
driving health care inflation and blocking more affordable alternatives, like
generics and biosimilars, from reaching American patients and lowering prices
in the marketplace,” said CSRxP executive director Lauren Aronson. “Big Pharma
opposes market-based solutions that would lower prescription drug prices by
falsely claiming egregious prices and extended monopolies are justified by
investments in innovation, despite routinely spending more on marketing than
research and development (R&D) and numerous studies debunking any connection
between prices set by brand name manufacturers and clinical value for patients
or investments in R&D.”



“As Members of the Committee meet to consider how to make medicines more
affordable, CSRxP encourages lawmakers to reject Big Pharma’s debunked rhetoric
on innovation and build momentum behind bipartisan solutions to bring more
affordable alternatives to market, more quickly, to effectively lower drug
prices for consumers,” Aronson continued.



Bipartisan, market-based solutions the Committee on HELP can advance to lower
drug prices for the American people by fostering greater competition include:

* Biosimilar Red Tape Elimination Act (S.1954
<[link removed]>)
* Medication Affordability and Patent Integrity Act (S.2658
<[link removed]>)
* Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY)
Act (S.2620
<[link removed]>)
* Increasing Transparency in Generic Drug Applications Act (S.1302
<[link removed]>)
* Ensuring Timely Access to Generics Act of 2025 (S.3014
<[link removed]>)
These policies would help remove barriers to greater competition, expand
access to biosimilars and other affordable alternatives and deliver meaningful
savings for patients and the U.S. health care system.



Read more about how biosimilar competition lowers out-of-pocket costs for
patientsHERE
<[link removed]>
.



Read more on how Big Pharma’s innovation rhetoric doesn’t hold up to scrutiny
HERE
<[link removed]>
.



Read more on how Big Pharma games the system to block competition and keep
drug prices highHERE
<[link removed]>
.



Read more on bipartisan, market-based solutions to hold Big Pharma accountable
HERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>